---
title: "Key facts: Novo Nordisk sells GLP‑1s via Hims & Hers;MACE down 42%/13%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286182536.md"
description: "Novo Nordisk partners with Hims & Hers to sell FDA-approved GLP-1 drugs to eligible customers, including Wegovy (injectable and oral) and Ozempic pens; expands retail access to these meds.1Novo Nordisk: once‑weekly semaglutide 2.4 mg cut MACE in SELECT perimenopausal women ~42% vs placebo and ~13% in postmenopausal women; subgroup difference not statistically significant.2"
datetime: "2026-05-13T02:03:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286182536.md)
  - [en](https://longbridge.com/en/news/286182536.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286182536.md)
---

# Key facts: Novo Nordisk sells GLP‑1s via Hims & Hers;MACE down 42%/13%

-   Novo Nordisk partners with Hims & Hers to sell FDA-approved GLP-1 drugs to eligible customers, including Wegovy (injectable and oral) and Ozempic pens; expands retail access to these meds.1
-   Novo Nordisk: once‑weekly semaglutide 2.4 mg cut MACE in SELECT perimenopausal women ~42% vs placebo and ~13% in postmenopausal women; subgroup difference not statistically significant.2

### Related Stocks

- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [NVOX.US](https://longbridge.com/en/quote/NVOX.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [XHS.US](https://longbridge.com/en/quote/XHS.US.md)
- [HIMY.US](https://longbridge.com/en/quote/HIMY.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Key facts: Novo Nordisk early −21.6% 64w; Rexall delivery Canada](https://longbridge.com/en/news/286343869.md)
- [Wegovy Liver Data Broadens Semaglutide Story For Novo Nordisk Investors](https://longbridge.com/en/news/286980981.md)
- [Novo Nordisk Discloses Gifted Share Transactions Linked to CFO Associates](https://longbridge.com/en/news/286260366.md)
- [CDSCO asks states, UTs to monitor surrogate promotion for GLP-1 drugs](https://longbridge.com/en/news/286925029.md)
- [Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial](https://longbridge.com/en/news/286239982.md)